{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ceftazidime%2Favibactam", "query": { "intervention": "Ceftazidime/avibactam" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ceftazidime%2Favibactam&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T03:09:10.365Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03243864", "title": "Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Renal Failure", "Bacterial Infections", "Critical Illness" ], "interventions": [ { "name": "Ceftazidime-avibactam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Temple University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-03-13", "completion_date": "2020-10-21", "has_results": false, "last_update_posted_date": "2019-04-10", "last_synced_at": "2026-09-24T03:09:10.365Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03243864" }, { "nct_id": "NCT02732327", "title": "Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Febrile Neutropenia" ], "interventions": [ { "name": "CAZ-AVI", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" }, { "name": "Linezolid", "type": "DRUG" }, { "name": "Cefepime", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" }, { "name": "Piperacillin/tazobactam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2016-05-17", "completion_date": "2016-06-27", "has_results": true, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-09-24T03:09:10.365Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02732327" }, { "nct_id": "NCT05977868", "title": "Comparing Oral Versus Parenteral Antimicrobial Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Endovascular Infection", "Bone and Joint Infection", "Skin and Soft Tissue Infection", "Pulmonary Infection", "Gastrointestinal Infection", "Genitourinary Infection" ], "interventions": [ { "name": "Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid", "type": "DRUG" }, { "name": "Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2023-08-04", "completion_date": "2025-02-14", "has_results": true, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-09-24T03:09:10.365Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05977868" }, { "nct_id": "NCT01290900", "title": "A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Male Volunteers" ], "interventions": [ { "name": "NXL104", "type": "DRUG" }, { "name": "Ceftaroline", "type": "DRUG" }, { "name": "Placebo Infusion", "type": "DRUG" }, { "name": "Ceftazidime", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 54, "start_date": "2011-02", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2017-09-01", "last_synced_at": "2026-09-24T03:09:10.365Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01290900" }, { "nct_id": "NCT01291602", "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Male and Female Japanese Volunteers" ], "interventions": [ { "name": "NXL104", "type": "DRUG" }, { "name": "CAZ104", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "20 Years to 45 Years" }, "enrollment_count": 15, "start_date": "2011-02", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2017-09-01", "last_synced_at": "2026-09-24T03:09:10.365Z", "location_count": 2, "location_summary": "Glendale, California • Baltimore, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01291602" }, { "nct_id": "NCT04126031", "title": "Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gram-negative Bacterial Infection" ], "interventions": [ { "name": "Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3", "type": "DRUG" }, { "name": "Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "88 Days", "sex": "ALL", "summary": "0 Days to 88 Days" }, "enrollment_count": 48, "start_date": "2020-01-14", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2024-03-26", "last_synced_at": "2026-09-24T03:09:10.365Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04126031" }, { "nct_id": "NCT01893346", "title": "Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Infections" ], "interventions": [ { "name": "CAZ-AVI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Months to 17 Years" }, "enrollment_count": 35, "start_date": "2013-07", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-09-06", "last_synced_at": "2026-09-24T03:09:10.365Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Orange, California • San Diego, California + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01893346" }, { "nct_id": "NCT01644643", "title": "Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Complicated Urinary Tract Infection", "Complicated Intra-abdominal Infection" ], "interventions": [ { "name": "Ceftazidime - Avibactam ( CAZ-AVI)", "type": "DRUG" }, { "name": "Best Available Therapy", "type": "DRUG" }, { "name": "Metronidazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 345, "start_date": "2013-01", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-09-29", "last_synced_at": "2026-09-24T03:09:10.365Z", "location_count": 2, "location_summary": "Shreveport, Louisiana • Lima, Ohio", "locations": [ { "city": "Shreveport", "state": "Louisiana" }, { "city": "Lima", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644643" }, { "nct_id": "NCT01599806", "title": "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis" ], "interventions": [ { "name": "Ceftazidime - Avibactam ( CAZ-AVI)", "type": "DRUG" }, { "name": "Doripenem", "type": "DRUG" }, { "name": "Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)", "type": "DRUG" }, { "name": "or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 641, "start_date": "2012-10", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2017-09-06", "last_synced_at": "2026-09-24T03:09:10.365Z", "location_count": 3, "location_summary": "Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Indiana", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01599806" }, { "nct_id": "NCT01499290", "title": "Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Complicated Intra-Abdominal Infection" ], "interventions": [ { "name": "CAZ-AVI", "type": "DRUG" }, { "name": "Metronidazole", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 493, "start_date": "2012-03", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-09-06", "last_synced_at": "2026-09-24T03:09:10.365Z", "location_count": 4, "location_summary": "Chula Vista, California • San Diego, California • St Louis, Missouri + 1 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Somers Point", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499290" } ] }